Navigation Links
DURECT to Present at the BMO Capital Markets Healthcare Conference
Date:7/28/2009

CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5 at 4:00 pm Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York City. A webcast of the presentation will be accessible at: http://www.bmocm.com/conferences/2009healthcare/webcast/.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
2. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
3. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
4. DURECT to Participate in Cowen and Company Healthcare Conference
5. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation to Participate in Upcoming Healthcare Conferences
9. DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
10. DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
11. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators ... often saves lives. However, if one isn’t accessible in certain locations, the risk ... defibrillation, I came up with this idea," said an inventor from Ridgecrest, Calif. ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE is pleased ...  , Molli C., a graduate student from Sonora, California, who will begin her ... St. Thomas University in Miami, Florida, was selected from a pool of more ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... rooms is celebrating the one year anniversary of its Houston-Fallbrook facility. , ... Dr. Otinwa, Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has ...
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, customers ... Mart has stated to offer wearable, and customers can find clothing at discounted ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and Company ... and secondary endpoint data for lasmiditan, an investigational, oral, ... demonstrated statistically significant improvements compared to placebo in the ... today at the 18th Congress of the International Headache ... "The data presented today demonstrate lasmiditan,s potential to ...
(Date:9/7/2017)... nearly two decades, New Life Agency has been committed to providing the ... Life Agency announces a powerful three-way partnership designed to deliver substantial savings ... ... http://www.schrafts2.com/ (PRNewsfoto/PharmaCareCard) ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)... Sept. 7, 2017 NuvoAir (formerly called ... announced today a partnership with Novartis Pharma AG to distribute ... position as the leading mobile spirometry platform and Novartis, commitment ... ... ...
Breaking Medicine Technology: